Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial

被引：3
|
作者：
Chatta, G. S. [1 ]
Feinstein, T. M. [1 ]
Appleman, L. J. [1 ]
Friedland, D. M. [1 ]
Jacobs, S. A. [1 ]
Evans, T. L. [1 ]
Earle, M. F. [1 ]
Strausser, H. M. [1 ]
Gooding, W. E. [1 ]
Lenzner, D. [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5148
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Chi, K. N.
    Vaishampayan, U.
    Hotte, S.
    Vogelzang, N.
    Alumkal, J.
    Agrawal, M.
    Nydam, T. M.
    Fandi, A.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel
    Bourdoumis, Andreas
    Chrisofos, Michael
    Stasinou, Theodora
    Christopoulos, Panagiotis
    Mourmouris, Panagiotis
    Kostakopoulos, Athanasios
    Deliveliotis, Charalambos
    ANTICANCER RESEARCH, 2015, 35 (05) : 3075 - 3079
  • [5] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [6] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [7] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    White, Ralph de Vere
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Gulley, James L.
    Arlen, Philip M.
    Woo, Sukyung
    Steinberg, Seth M.
    Wright, John J.
    Parnes, Howard L.
    Trepel, Jane B.
    Lee, Min-Jung
    Kim, Yeong Sang
    Sun, Haihao
    Madan, Ravi A.
    Latham, Lea
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
  • [10] Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Ning, Yang-Min
    Adesunloye, Bamidele A.
    Huang, Xuan
    Harold, Nancy
    Couvillon, Anna
    Chun, Guinevere
    Cordes, Lisa
    Sissung, Tristan
    Beedie, Shaunna L.
    Dawson, Nancy A.
    Theoret, Marc R.
    McLeod, David G.
    Rosner, Inger
    Trepel, Jane B.
    Lee, Min-Jung
    Tomita, Yusuke
    Lee, Sunmin
    Chen, Clara
    Steinberg, Seth M.
    Arlen, Philip M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2016, 118 (04) : 590 - 597
12345